Aerpio Pharmaceuticals to Report Year Ended December 31, 2019 Financial Results on Monday, March 16, 2020
12 Marzo 2020 - 10:00PM
Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical
company focused on developing compounds that activate Tie2 to treat
ocular diseases and diabetic complications, will release its
financial results for the fourth quarter and full year ended
December 31, 2019, before the market open on Monday, March 16,
2020, and host a webcast and conference call at 8:30am ET.
Monday, March 16th @ 8:30am
ET |
Investors: |
877-407-9716 |
International Investors: |
201-493-6779 |
Conference ID: |
13700254 |
Webcast: |
http://public.viavid.com/index.php?id=138519 |
About Aerpio
PharmaceuticalsAerpio Pharmaceuticals, Inc. is a
biopharmaceutical company focused on developing compounds that
activate Tie2 to treat ocular diseases and diabetic complications.
Recently published mouse and human genetic data implicate the
Angpt/Tie2 pathway in maintenance of Schlemm’s canal, a critical
component of the conventional outflow tract. The Company’s lead
compound, AKB-9778, a first-in-class small molecule inhibitor of
vascular endothelial protein tyrosine phosphatase (“VE-PTP”), is
being developed as a potential treatment for open angle glaucoma,
and the Company intends to investigate the therapeutic potential of
AKB-9778 in other indications. The Company is also evaluating
development options for ARP-1536, a humanized monoclonal antibody,
for its therapeutic potential in the treatment of diabetic vascular
complications including nephropathy and diabetic macular edema
(“DME”). The Company’s third asset is a bispecific antibody that
binds both VEGF and VE-PTP which is designed to inhibit VEGF
activation and activate Tie2. This bispecific antibody has the
potential to be an improved treatment for wet age-related macular
degeneration and DME via intravitreal injection. Finally, the
Company has exclusively out-licensed AKB-4924 (now called GB004), a
first-in-class small molecule inhibitor of hypoxia-inducible
factor-1 (HIF). GB004 is being developed by AKB-4924’s exclusive
licensor, Gossamer Bio, Inc. (Nasdaq: GOSS), in return for an
upfront payment of $20 million, future potential development,
regulatory, and sales milestones of up to $400 million, and
royalties on worldwide net sales. For more information, please
visit www.aerpio.com.
ContactsAerpio Pharmaceuticals, Inc. Gina
MarekVP of Financegmarek@aerpio.com
Grafico Azioni Aerpio Pharmaceuticals (NASDAQ:ARPO)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Aerpio Pharmaceuticals (NASDAQ:ARPO)
Storico
Da Mag 2023 a Mag 2024
Notizie in Tempo Reale relative a Aerpio Pharmaceuticals Inc (NASDAQ): 0 articoli recenti
Più Articoli Notizie